Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19

Next Previous
X
Search
Trial Profile

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 13 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molnupiravir (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MOVe-OUT
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 12 Sep 2023 This trial has been completed in Germany (Date of the global end of the trial: 05-May-2022), according to the European Clinical Trials Database record.
    • 19 Jun 2023 Results of secondary and post hoc analyses of participants self-reported symptoms in this study, assessing impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms, published in the Clinical Infectious Diseases
    • 05 Apr 2023 Results investigating the relationship between beta D-N4-hydroxycytidine (NHC) pharmacokinetics (PK) and clinical outcomes in patients with mild to moderate COVID19 published in the Clinical Pharmacology and Therapeutics,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top